Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
3T Biosciences Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are distributed across 4 distinct examiners and 3 distinct art units. This distribution indicates that the company is engaging with multiple specialized review groups at the USPTO. The presence of 3 distinct art units suggests that the pending applications cover several technical classifications.
RAYMONDA, MATTHEW HAROLD is the busiest examiner for the portfolio, currently handling 1 pending office action. This examiner is responsible for 1 of the 4 total pending actions identified in the company data. The workload is spread among the various examiners, meaning that the portfolio's progress is not dependent on the pace of a specific individual.
The Biotechnology & Pharmaceuticals sector represents the current active prosecution front for the company. Successful prosecution will require addressing the concerns of RAYMONDA, MATTHEW HAROLD and the other officials assigned to the cases within the 3 assigned art units. Monitoring the status of the 4 pending office actions is essential for understanding the company's near-term intellectual property trajectory.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAYMONDA, MATTHEW HAROLD | 1 | 35.7% | +55.0% |
| PAK, MICHAEL D | 1 | 58.3% | +30.4% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 49d overdue |
| 18157618 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | PAK, MICHAEL D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800993 | YEAST DISPLAY LIBRARIES, ASSOCIATED COMPOSITIONS, AND ASSOCIATE METHODS OF USE | ESPINOSA, CLAUDIA EDILMA | 89d overdue |
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 49d overdue |
| 18685109 | PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use | RAYMONDA, MATTHEW HAROLD | — |
| 18157618 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | PAK, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1633 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685109 | PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use | RAYMONDA, MATTHEW HAROLD | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18157618 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | PAK, MICHAEL D | 1674 | §103§112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§103§112 | Final Rejection | 49d overdue | Pending | Jan 20, 2023 |
| 17800993 | YEAST DISPLAY LIBRARIES, ASSOCIATED COMPOSITIONS, AND ASSOCIATE METHODS OF USE | ESPINOSA, CLAUDIA EDILMA | 1654 | §103DP | Final Rejection | 89d overdue | Pending | Aug 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial